Approved Risk Evaluation and Mitigation Strategies (REMS)

Contact Us | REMS Basics | Gov Delivery Get REMS Email Alerts | Reports & Data Files

Tysabri (natalizumab)
BLA #125104
REMS last update: 10/14/2016



What is the purpose of the REMS?

The goals of the Tysabri REMS are:

  1. To inform prescribers, infusion center healthcare providers, and patients about the risk of progressive multifocal leukoencephalopathy (PML) associated with TYSABRI including the increased risk of PML with longer treatment duration, prior immunosuppressant use and the presence of anti-JCV antibodies.
  2. To warn against concurrent use with antineoplastic, immunosuppressant, or immunomodulating agents, and in patients who are immunocompromised.
  3. To promote early diagnosis of PML and timely discontinuation of TYSABRI in the event of suspected PML.

What do participants need to know?

Below is a general overview of the REMS for all REMS participants (e.g., patients, pharmacies, and healthcare providers). See the application holder(s) REMS Website or the approved REMS materials for more information.

View application holder(s) REMS Website See Disclaimer page regarding links to external sites

Healthcare Providers who prescribe Tysabri must

To become certified to prescribe
Before treatment initiation
During treatment; at 3 and 6 months after the first infusion and every 6 months thereafter until treatment discontinuation
  • Assess the patient’s signs and symptoms for progressive multifocal leukoencephalopathy (PML).
During treatment; every 6 months
At treatment discontinuation
After treatment discontinuation; at 6 months
At all times
  • Report cases of PML, hospitalizations due to opportunistic infection, or deaths to sponsor.

Patients who are prescribed Tysabri

Before the first prescription
During treatment
  • Be monitored for signs and symptoms of progressive multifocal leukoencephalopathy (PML).
After treatment discontinuation
  • Be monitored for signs and symptoms of progressive multifocal leukoencephalopathy (PML).
At all times
  • Inform the prescriber if any new or worsening symptoms that persist over several days, especially nervous system symptoms.

Pharmacies that dispense Tysabri must

To become certified to dispense
At all times
  • Comply with audits carried out by the sponsor or to ensure that all processes and procedures are in place and are being followed.

Infusion centers that dispense Tysabri must

To become certified to dispense
At all times
  • Comply with audits carried out by the application holder or to ensure that all processes and procedures are in place and are being followed.

What materials are included in the REMS?

The REMS includes a REMS Document. In addition, the REMS includes the following materials intended for patients and healthcare providers. For a specific Medication Guide of a product in the Tysabri REMS, see the DailyMed link(s).
Material Name Material Name Link
12 Week Questionnaire for Crohn's Disease (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Tysabri_2016-10-14_12_Week_Questionnaire_for_Crohns_Disease.pdf
6-Month Discontinuation Questionnaire (CD) (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Tysabri_2016-10-14_6_Month_Discontinuation_Questionnaire_CD.pdf
6-Month Discontinuation Questionnaire (MS) (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Tysabri_2016-10-14_6_Month_Discontinuation_Questionnaire_MS.pdf
Certified Pharmacy Enrollment Form (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Tysabri_2016-10-14_Certified_Pharmacy_Enrollment_Form.pdf
Change Prescriber Authorization Form (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Tysabri_2016-10-14_Change_Prescriber_Authorization_Form.pdf
Helpful Information for Evaluation of New Neurologic Symptoms in Patients Receiving Tysabri (MS) (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Tysabri_2016-10-14_Helpful_Information_for_Evaluation_of_New_Neurological_Symptoms_in_Patients_Receiving_Tysabri_MS .pdf
Infusion Site Enrollment Form (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Tysabri_2016-10-14_Infusion_Site_Enrollment_Form.pdf
Initial Discontinuation Questionnaire (CD) (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Tysabri_2016-10-14_Initial_Discontinuation_Questionnaire_Crohns_Disease.pdf
Initial Discontinuation Questionnaire (MS) (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Tysabri_2016-10-14_Initial_Discontinuation_Questionnaire_MS.pdf
Patient Status Report and Reauthorization Questionnaire (CD) (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Tysabri_2016-10-14_Patient_Status_Report_and_Reauthorization_Questionnaire_Crohn's_Disease.pdf
Patient Status Report and Reauthorization Questionnaire (MS) (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Tysabri_2016-10-14_Patient_Status_Report_and_Reauthorization_Questionnaire_MS.pdf
Pre-Infusion Patient Checklist (combined MS and CD) (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Tysabri_2016-10-14_Pre_Infusion_Patient_Checklist.pdf
Prescriber/Patient Enrollment Form (CD) (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Tysabri_2016-10-14_Presciber_Patient_Enrollment_Form_CD.pdf
Prescriber/Patient Enrollment Form (MS) (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Tysabri_2016-10-14_Prescriber_Patient_Enrollment_Form_MS.pdf
REMS document (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Tysabri_2016-10-14_REMS_Document .pdf
REMS full (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Tysabri_2016-10-14-2016_Full.pdf
TOUCH On-Line REMS Website Screenshots (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Tysabri_2016-10-14_REMS_Website_Screenshots.pdf
TOUCH Prescribing Program Educational Slide Set (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Tysabri_2016-10-14_Prescribing_Program_Educational_Slide_Set .pdf
TOUCH Prescribing Program Overview (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Tysabri_2016-10-14_Prescribing_Program_Overview.pdf
Understanding PML for Gastroenterologists (CD) (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Tysabri_2016-10-14_Understanding_PML_Gastroenterologists_CD.pdf

What updates have been made to the REMS?

Date Summary of change
10/14/2016 Revised to correct typographical error(s).
09/22/2016 Modified to:

  1. Change the REMS to be consistent with safety labeling changes approved on May 18, 2016. The approved safety labeling change included the addition of “Periodic monitoring for radiographic signs consistent with PML should be considered to allow for an early diagnosis of PML. Lower PML-related mortality and morbidity have been reported following Tysabri discontinuation in patients with PML who were initially asymptomatic compared to patients with PML who had characteristic clinical signs and symptoms at diagnosis” within Section 5.1—Progressive Multifocal Leukoencephalopathy of the prescribing information.
  2. Change the sponsor name change from Biogen Idec to Biogen in the REMS document and all REMS materials.
  3. Update the list of immunosuppressants, antineoplastics, and immunomodulators with a recently approved medication for multiple sclerosis (Zinbryta [daclizumab]) in the REMS materials.
  4. Change the signature statements to enable certified prescribers to delegate the completion of the forms to individuals within their office who are not certified prescribers in the reauthorization and discontinuation status forms.
  5. Make format and editorial changes, typographical corrections, and update version and copyright dating throughout the REMS materials.
  6. Delete the REMS call center hours of availability from all REMS materials.
05/12/2015 Modified to:

  1. Be consistent with revisions to approved labeling in the Medication Guide and REMS forms and materials.
  2. Reflect your current trademark guidelines and the new version number in the appended REMS materials.
  3. Include products approved for multiple sclerosis and Crohn’s disease since the last REMS modification in the Prescriber-Patient Enrollment Forms and Pre-Infusion Patient Checklists.
  4. Include new products in the lists of immunomodulatory or immunosuppressant products the patient currently receives or has received in the previous 6 months in the Patient Status Report and Reauthorization Questionnaires and the Patient Initial Discontinuation Questionnaire—CD.
12/15/2013 Modified to reflect the revision to the indication statement language and the new risk information regarding hepatotoxicity, meningitis, and encephalitis being approved with these supplements in the REMS document, multiple REMS forms and materials, and the Medication Guide.
05/24/2013 Modified to include information about monitoring of PML after discontinuation of Tysabri (natalizumab) in the Medication Guide, REMS document and the REMS materials (e.g., Prescriber/Patient Enrollment Forms and Reauthorization and Discontinuation Questionnaires for Multiple Sclerosis and Crohn’s Disease patients and the Understanding PML for Gastroenterologists document).
01/20/2012 Modified to include information about PML risk stratification in the Medication Guide, REMS document and REMS materials.
10/07/2011 Approval of the REMS.

Disclaimer: This webpage provides general information about REMS programs to various REMS participants (e.g., patients, pharmacies, and healthcare providers). The summary information provided herein is not comprehensive and may not include all of the information relevant to REMS participants. This webpage does not constitute a replacement, modification, or revision of the approved REMS document, including any appended REMS materials. Refer to the approved REMS document for complete information on the REMS requirements for each approved application.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English